NIH Funding Secured for Development Through Phase 1 of Novel Antibiotic Candidate CRS0540

Jul 1, 2020 | Press Releases

Crestone, Inc. Secures NIH Funding for Development Through Phase 1 of Novel Antibiotic Candidate CRS0540, A Novel Inhibitor of DNA Replication in Gram-positive Pathogens.

Learn More:

https://www.businesswire.com/news/home/20200701005065/en/Crestone-Secures-NIH-Funding-Development-Phase-1